CTLA4 and neoplasm: We found that PD1 blockade alone was sufficient to reduce tumor growth in the MC38 model, while treatment with both anti-PD1 and anti-CTLA4 was required to inhibit growth of B16F10 tumors (Fig. 1A, B).